The landscape overview of CD47-based immunotherapy for hematological malignancies

作者全名："Yang, Hua; Xun, Yang; You, Hua"

作者地址："[Yang, Hua; Xun, Yang] Foshan Univ, Sch Med, Dept Basic Med & Biomed Engn, Foshan 528000, Guangdong, Peoples R China; [You, Hua] Chongqing Med Univ, Childrens Hosp, Dept Pediat Hematol & Oncol, Lab Excellence Syst Biomed Pediat Oncol, Chongqing 401122, Peoples R China; [You, Hua] Chongqing Med Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth & Disorders, Minist Educ,Chongqing Key Lab Pediat,Key Lab Child, Chongqing 401122, Peoples R China"

通信作者："You, H (通讯作者)，Chongqing Med Univ, Childrens Hosp, Dept Pediat Hematol & Oncol, Lab Excellence Syst Biomed Pediat Oncol, Chongqing 401122, Peoples R China.; You, H (通讯作者)，Chongqing Med Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth & Disorders, Minist Educ,Chongqing Key Lab Pediat,Key Lab Child, Chongqing 401122, Peoples R China."

来源：BIOMARKER RESEARCH

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000926065000001

JCR分区：Q1

影响因子：9.5

年份：2023

卷号：11

期号：1

开始页：　

结束页：　

文献类型：Review

关键词：CD47; SIRP alpha; Targeted therapies; Clinical trials; Immunotherapy

摘要："Extensive clinical and experimental evidence suggests that macrophages play a crucial role in cancer immunotherapy. Cluster of differentiation (CD) 47, which is found on both healthy and malignant cells, regulates macrophage-mediated phagocytosis by sending a ""don't eat me "" signal to the signal regulatory protein alpha (SIRP alpha) receptor. Increasing evidence demonstrates that blocking CD47 interaction with SIRP alpha can enhance cancer cell clearance by macrophages. Additionally, inhibition of CD47/SIRP alpha interaction can increase antigen cross-presentation, leading to T-cell priming and an activated adaptive antitumor immune response. Therefore, inhibiting CD47/SIRP alpha axis has a significant impact on tumor immunotherapy. Studies on CD47 monoclonal antibodies are at the forefront of research, and impressive results have been obtained. Nevertheless, hematotoxicity, especially anemia, has become the most common adverse effect of the CD47 monoclonal antibody. More specific targeted drugs (i.e., bispecific antibodies, SIRP alpha/Fc fusion protein antibodies, and small-molecule inhibitors) have been developed to reduce hematotoxicity. Here, we review the present usage of CD47 antagonists for the treatment of lymphomas and hematologic neoplasms from the perspectives of structure, function, and clinical trials, including a comprehensive overview of the drugs in development."

基金机构："National Natural Science Foundation of China [82203844, 82203213, 81911530169]; Basic and Applied Basic Research Project of Guangdong Province [2020A1515111201]; University Special Innovative Research Program of the Department of Education of Guangdong Province [2020KQNCX073]"

基金资助正文："This study was supported by the National Natural Science Foundation of China (82203844, 82203213, 81911530169), Basic and Applied Basic Research Project of Guangdong Province (2020A1515111201), and University Special Innovative Research Program of the Department of Education of Guangdong Province (2020KQNCX073)."